Close Menu

NEW YORK (GenomeWeb) – Locus Biosciences said today that is has acquired EpiBiome's high-throughput bacteriophage discovery platform.

Locus is developing CRISPR-Cas3-engineered precision antibacterial products, and aims to pair EpiBiome's phage isolation and characterization system with its own CRISPR-based synthetic biology platform to develop products to treat antibiotic-resistant bacterial infections and precisely edit the microbiome. Terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.

A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.

Broad Institute researchers describe an approach they've dubbed "DNA microscopy."

In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.